CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER

Background: Pathological complete response (pCR) after pembrolizumab-based neoadjuvant chemoimmunotherapy predicts improved outcomes in early triple-negative breast cancer (TNBC), but circulating immune determinants of response remain poorly characterized. Methods: The study included 64 patients with early TNBC treated with pembrolizumab-based neoadjuvant chemoimmunotherapy. Flow cytometry analyzed 125 peripheral-blood specimens collected at baseline, during treatment and before surgery. Baseline PBMCs from 22 patients underwent scRNA-seq, generating 135,271 quality-controlled cells. Analyses used nonparametric tests, effect sizes, FDR correction and sensitivity analyses. Results: Baseline scRNA-seq identified response-associated transcriptional differences. Patient-level pseudo-bulk analysis revealed enrichment of TNF-alpha/NF-kappaB signaling in cytotoxic T/NK and B cells from non-pCR patients (global q<=3.94e-7), together with MYC targets and mTORC1 signaling in cytotoxic T/NK cells (both global q=7.00e-5). T-cell analyses suggested preserved naive/memory features in pCR, while a higher proportion of CX3CR1-expressing cells within the CD4 memory/activation-like compartment was associated with pCR (q=0.0157; AUC=0.949). In B cells, pCR was associated with a nominally higher naive-like program score (P=0.029; q=0.059), supported by higher IGHM and IGHD signals, whereas XBP1 was higher in non-pCR. Flow cytometry identified treatment-associated B-cell remodeling. At pre-surgery, switched-memory B-cell CD38 balance was higher in pCR than non-pCR patients (62.6% versus 50.0%; P=0.0086; q=0.0667; Cliff's delta=0.651; AUC=0.825) and remained nominally significant in leave-one-patient-out analyses. Early increases in unswitched-memory B-cell CD38 balance were numerically greater in non-pCR patients, whereas pre-surgery switched-memory B-cell CD38 balance was higher in pCR patients. Conclusions: Baseline inflammatory and metabolic pathway enrichment was associated with non-pCR, whereas pCR-associated T-cell findings included a CD4 memory/activation-associated CX3CR1 signal and trends towards preserved naive/memory features. Together with time- and compartment-dependent B-cell remodeling, these findings nominate circulating transcriptional states and CD38-defined B-cell dynamics for prospective validation as candidate biomarkers of pathological response.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-20
DOI
https://doi.org/10.64898/2026.11.19.26368490
Primary Topic
Breast Cancer Treatment Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER

Javier Pascual, Rafael López‐López, Jesús Velasco-Suelto, Clotilde Costa et al.
6 links
medRxiv
Breast Cancer Treatment Studies
preprint

CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER

Javier Pascual, Rafael López‐López, Jesús Velasco-Suelto, Clotilde Costa, Maria Rosario Chica-Parrado, María Victoria Ortega-Jiménez, M.I. Hierro-Martín, Martina Álvarez, María Elena Quirós-Ortega, Enríque Álava, Esperanza López-López, Patricia Palacios Ozores, Roberto Piñeiro, Begoña Jiménez-Rodríguez, Iñaki Comino‐Méndez, Álvaro González-Ortiz, María Emilia Domínguez, Antonia Márquez, B. Pajares, Ana Godoy, Emilio Alba, Patricia Chaves-Guerrero, Nuria Ribelles, Pilar Cantizani
preprint en

Abstract

Background: Pathological complete response (pCR) after pembrolizumab-based neoadjuvant chemoimmunotherapy predicts improved outcomes in early triple-negative breast cancer (TNBC), but circulating immune determinants of response remain poorly characterized. Methods: The study included 64 patients with early TNBC treated with pembrolizumab-based neoadjuvant chemoimmunotherapy. Flow cytometry analyzed 125 peripheral-blood specimens collected at baseline, during treatment and before surgery. Baseline PBMCs from 22 patients underwent scRNA-seq, generating 135,271 quality-controlled cells. Analyses used nonparametric tests, effect sizes, FDR correction and sensitivity analyses. Results: Baseline scRNA-seq identified response-associated transcriptional differences. Patient-level pseudo-bulk analysis revealed enrichment of TNF-alpha/NF-kappaB signaling in cytotoxic T/NK and B cells from non-pCR patients (global q<=3.94e-7), together with MYC targets and mTORC1 signaling in cytotoxic T/NK cells (both global q=7.00e-5). T-cell analyses suggested preserved naive/memory features in pCR, while a higher proportion of CX3CR1-expressing cells within the CD4 memory/activation-like compartment was associated with pCR (q=0.0157; AUC=0.949). In B cells, pCR was associated with a nominally higher naive-like program score (P=0.029; q=0.059), supported by higher IGHM and IGHD signals, whereas XBP1 was higher in non-pCR. Flow cytometry identified treatment-associated B-cell remodeling. At pre-surgery, switched-memory B-cell CD38 balance was higher in pCR than non-pCR patients (62.6% versus 50.0%; P=0.0086; q=0.0667; Cliff's delta=0.651; AUC=0.825) and remained nominally significant in leave-one-patient-out analyses. Early increases in unswitched-memory B-cell CD38 balance were numerically greater in non-pCR patients, whereas pre-surgery switched-memory B-cell CD38 balance was higher in pCR patients. Conclusions: Baseline inflammatory and metabolic pathway enrichment was associated with non-pCR, whereas pCR-associated T-cell findings included a CD4 memory/activation-associated CX3CR1 signal and trends towards preserved naive/memory features. Together with time- and compartment-dependent B-cell remodeling, these findings nominate circulating transcriptional states and CD38-defined B-cell dynamics for prospective validation as candidate biomarkers of pathological response.

medRxiv
Complejo Hospitalario Universitario de Santiago (ES), Hospital Regional Universitario de Málaga (ES), Centro de Investigación Biomédica en Red (ES), Instituto de Biomedicina de Sevilla (ES), Instituto de Investigación Sanitaria de Santiago (ES), Andalusian Centre for Nanomedicine and Biotechnology (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), Servicio Gallego de Salud (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Instituto de Investigación Biomédica de Málaga (ES), Universidad de Sevilla (ES), Universidad de Málaga (ES)
Instituto de Salud Carlos III, Agencia Estatal de Investigación, European Social Fund
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon